GlassScriptPhysician profile
Fred S Bodker
NPI 1417944208
$4,399.14
in general payments reported to CMS, 2019-2025
25 companies · $883 in 2025
The $883 reported for 2025 was more than what 76% of Ophthalmic Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $299).
See the full distribution for Ophthalmic Plastic and Reconstructive Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $467 · 2020: $185 · 2021: $813 · 2022: $721 · 2023: $590 · 2024: $740 · 2025: $883.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,213.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $969.44 | 2019-2023 | Tepezza |
| Amgen INC. | $757.98 | 2024-2025 | Tepezza |
| Alcon Vision LLC | $487.73 | 2020-2025 | Clareon Panoptix Pro, Rocklatan, Clareon |
| Sun Pharmaceutical Industries INC. | $305.74 | 2019-2025 | Cequa |
| Carl Zeiss Meditec USA, INC. | $240.84 | 2021-2022 | |
| Kala Pharmaceuticals, INC. | $239.80 | 2019-2022 | |
| Oyster Point Pharma, INC. | $230.81 | 2022-2025 | Tyrvaya |
| Dompe US, INC. | $146.64 | 2022-2025 | Oxervate |
| Genentech USA, INC. | $129.01 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $126.16 | 2020-2021 | |
| Coopervision INC. | $126.09 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $108.70 | 2023-2025 | Vyzulta, Miebo, Xiidra |
| Tarsus Pharmaceuticals, INC. | $106.95 | 2024 | Xdemvy |
| Biotissue Holdings INC. | $83.95 | 2019-2024 | |
| Aerie Pharmaceuticals, INC. | $66.11 | 2020-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $63.15 | 2020-2023 | |
| Allergan, INC. | $35.05 | 2019-2021 | |
| Glaukos Corporation | $34.95 | 2024 | Idose |
| Rxsight INC | $34.30 | 2023-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Thea Pharma INC. | $24.71 | 2023 | Iyuzeh |
| Lumenis, INC | $21.58 | 2021 | |
| Spark Therapeutics, INC. | $18.42 | 2022 | |
| Genzyme Corporation | $17.91 | 2019 | |
| Sight Sciences, INC. | $11.78 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $11.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fred Bodker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.